Zacks Research upgraded shares of Plus Therapeutics (NASDAQ:CNSY – Free Report) from a strong sell rating to a hold rating in a research report released on Thursday morning,Zacks reports.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce”.
Read Our Latest Research Report on CNSY
Plus Therapeutics Stock Performance
Shares of NASDAQ CNSY traded up $0.18 during midday trading on Thursday, hitting $0.95. 8,046,110 shares of the company’s stock were exchanged, compared to its average volume of 1,810,277. The firm has a fifty day simple moving average of $1.70. The company has a market cap of $7.21 million, a P/E ratio of -0.28 and a beta of 1.49. Plus Therapeutics has a twelve month low of $0.43 and a twelve month high of $18.89.
Plus Therapeutics (NASDAQ:CNSY – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.16). The business had revenue of $0.72 million during the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. On average, analysts anticipate that Plus Therapeutics will post -4.40 EPS for the current fiscal year.
About Plus Therapeutics
Plus Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company is based in Austin, Texas, and was formerly known as Cytori Therapeutics. Its lead investigational product, REYOBIQ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumors in the brain and central nervous system. The treatment is being studied for conditions including recurrent glioblastoma and leptomeningeal metastases.
Further Reading
- Five stocks we like better than Plus Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
